No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The prescribing information does not call for a renal dose reduction for this inhaled maintenance product. Limits and monitoring Verify the inhaler, active ingredients and indication. The renal guidance does not supply dialysis timing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 29, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding The label retains usual renal dosing in mild or moderate impairment at indexed GFR 30-90. Safety and effectiveness below 30 mL/min/1.73 m2 are unestablished. Limits and monitoring Assess volume status, potassium, and kidney function in susceptible patients. Verify age-specific guidance. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 32, posted Aug 13, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For adults and children age 2 years or older, reduce the usual dose by 25% at CrCl above 50 through 80, by 50% above 30 through 50, and by 75% above 10 through 30 mL/min. Limits and monitoring Renal dosing information for infants is unavailable. Confirm the formulation and the separate vision-risk monitoring requirements. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 40, posted Dec 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The prescribing information specifies no renal dose change for vismodegib. Limits and monitoring The effect of severe impairment on exposure is uncertain. The dosing statement does not establish dialysis timing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 15, posted Dec 10, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding If baseline eGFR is 45 mL/min/1.73 m2 or lower, voclosporin is not recommended unless the expected benefit outweighs the risk. Limits and monitoring Check the label's lower starting regimen if used in severe impairment and its eGFR monitoring and adjustment algorithm. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 12, posted Aug 27, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The label specifies no renal dosing modification for vorapaxar. Limits and monitoring Review the labeled cerebrovascular and bleeding contraindications before using the antiplatelet regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Oct 19, 2022 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The orally inhaled zanamivir product has low systemic availability and requires no renal dose adjustment. Limits and monitoring The source notes limited clinical documentation in severe renal insufficiency. Confirm the inhaled route and bronchospasm precautions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Jul 27, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding For adults maintained on HD or PD, or with Cockcroft-Gault CrCl below 15 mL/min, the IV zidovudine equivalent of the renal-adjusted oral regimen is approximately 1 mg/kg every 6-8 hours. Limits and monitoring Confirm route and weight. The source distinguishes the IV equivalent from the oral 100 mg dose. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 33, posted Oct 08, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Reduced kidney function does not require a renal dose change for immediate-release zolpidem. Limits and monitoring Confirm the immediate-release product, dosing instructions and risks of next-day impairment. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 1, posted Feb 10, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
